WO2021079986A1 - Composition bactériophage - Google Patents

Composition bactériophage Download PDF

Info

Publication number
WO2021079986A1
WO2021079986A1 PCT/JP2020/039901 JP2020039901W WO2021079986A1 WO 2021079986 A1 WO2021079986 A1 WO 2021079986A1 JP 2020039901 W JP2020039901 W JP 2020039901W WO 2021079986 A1 WO2021079986 A1 WO 2021079986A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
endolysin
amino acid
acid sequence
composition
Prior art date
Application number
PCT/JP2020/039901
Other languages
English (en)
Japanese (ja)
Inventor
英知 岩野
純平 藤木
中村　哲
久美子 スミス
豪紀 樋口
田村　豊
優 臼井
智 権平
Original Assignee
Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社
学校法人酪農学園
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2019/041541 external-priority patent/WO2021079435A1/fr
Application filed by Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社, 学校法人酪農学園 filed Critical Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社
Publication of WO2021079986A1 publication Critical patent/WO2021079986A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne une composition pour la lyse de Staphylococcus aureus ou une composition pour la prévention ou le traitement d'une maladie provoquée par Staphylococcus aureus, ladite composition comprenant, en tant que principes actifs, au moins un bactériophage choisi dans le groupe constitué par un bactériophage identifié sous le numéro d'accès NITE BP-693 et un bactériophage identifié sous le numéro d'accès NITE BP-694, et une endolysine qui est au moins une protéine choisie dans le groupe constitué par (a) une protéine présentant la séquence d'acides aminés représentée par SEQ ID NO : 1, (b) une protéine qui comprend une séquence d'acides aminés présentant au moins 80 % d'identité avec la séquence d'acides aminés représentée par SEQ ID NO : 1 et (c) une protéine qui comprend une séquence d'acides aminés présentant une substitution, une délétion, une addition et/ou une insertion d'un ou plusieurs acides aminés dans la séquence d'acides aminés représentée par SEQ ID NO : 1.
PCT/JP2020/039901 2019-10-23 2020-10-23 Composition bactériophage WO2021079986A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPPCT/JP2019/041541 2019-10-23
PCT/JP2019/041541 WO2021079435A1 (fr) 2019-10-23 2019-10-23 Composition bactériophage
PCT/JP2020/004908 WO2021079536A1 (fr) 2019-10-23 2020-02-07 Composition bactériophage
JPPCT/JP2020/004908 2020-02-07

Publications (1)

Publication Number Publication Date
WO2021079986A1 true WO2021079986A1 (fr) 2021-04-29

Family

ID=75620113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/039901 WO2021079986A1 (fr) 2019-10-23 2020-10-23 Composition bactériophage

Country Status (1)

Country Link
WO (1) WO2021079986A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011050373A (ja) * 2008-12-26 2011-03-17 Wako Pure Chem Ind Ltd スタフィロコッカス・アウレウス溶菌性バクテリオファージ
WO2020032232A1 (fr) * 2018-08-10 2020-02-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Préparation de bactériophages

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011050373A (ja) * 2008-12-26 2011-03-17 Wako Pure Chem Ind Ltd スタフィロコッカス・アウレウス溶菌性バクテリオファージ
WO2020032232A1 (fr) * 2018-08-10 2020-02-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Préparation de bactériophages

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Our students and graduate students received each award at the 6th Bovine Mastitis Summer Camp", RAKUNO GAKUEN UNIVERSITY HOMEPAGE, no. 54, 2019, Retrieved from the Internet <URL:https://www.rakuno.ac.JP/archives/3013.html> *
FUJIKI JUMPEI; NAKAMURA TOMOHIRO; FURUSAWA TAKAAKI; OHNO HAZUKI; TAKAHASHI HIROMICHI; KITANA JUNYA; USUI MASARU; HIGUCHI HIDETOSHI: "Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage", PHARMACEUTICALS, vol. 11, no. 1, 2018, pages 1 - 19, XP055819272 *
HIDETOMO IWANO , JUMPEI FUJIKI , HIDETOSHI HIGUCHI, YASUNORI TANJI , YUTAKA TAMURA: "WS02-04: Application of the bacteriophage therapy to the veterinary medicine", NIPPON SAIKINGAKU ZASSHI, vol. 74, no. 1, 25 March 2019 (2019-03-25), pages 25, XP055819547, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/jsb/74/1/74_23/_pdf/-char/ja> [retrieved on 20200303] *
IWANO, HIDETOMO: "Application of bacteriophage against antimicrobial resistant bacterial infection", PROGRAMS AND ABSTRACTS OF THE 85TH HOKKAIDO BRANCH ACADEMIC GENERAL CONFERENCE OF JAPANESE SOCIETY FOR BACTERIOLOGY, 23 August 2019 (2019-08-23), Retrieved from the Internet <URL:http://www.jsb-hokkaido.org/wp/wp-content/uploads/2019/08/8f2dabf775ac17dc5cdc2518f76403c4.pdf> *
JUNYA KITANA , HIROMICHI TAKAHASHI , JUMPEI FUJIKI , TOMOHIRO NAKAMURA , MASARU USUI , HIDETOSHI HIGUCHI , YUME INOMATA , HIDETOMO: "DP03-02 (P-274): Investigation of Phage Selection Method for Construction of Bacteriophage Library against Staphylococcus aureus", NIPPON SAIKINGAKU ZASSHI, vol. 74, no. 1, 25 March 2019 (2019-03-25), pages 51, XP055819551, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/jsb/74/1/74_44/_pdf/-char/ja> *
KITANA, JUNYA ET AL.: "Examination for the method to evaluate bactericidal activity aiming for the construction of bacteriophage library for Staphylococcus aureus", PROGRAMS AND ABSTRACTS OF THE 85TH HOKKAIDO BRANCH ACADEMIC GENERAL CONFERENCE OF JAPANESE SOCIETY FOR BACTERIOLOGY, 23 August 2019 (2019-08-23), Retrieved from the Internet <URL:http://www.jsb-hokkaido.org/wp/wp-content/uploads/2019/08/8f2dabf775ac17dc5cdc2518f76403c4.pdf> *

Similar Documents

Publication Publication Date Title
KR100781669B1 (ko) 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
JP6110515B2 (ja) 新規なバクテリオファージ及びこれを含む抗菌組成物
US8232370B2 (en) Antimicrobial protein specific to Staphylococcus aureus
JP6769871B2 (ja) Ｅ．ｃｏｌｉ感染のファージを用いての治療
EP2961834B1 (fr) Nouveau bactériophage et composition antibactérienne comprenant celui-ci
Celia et al. Characterization of a bacteriophage lysin (Ply700) from Streptococcus uberis
US20220370547A1 (en) Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof
US8377866B2 (en) Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
JP5720045B2 (ja) スタフィロコッカス・アウレウス溶菌性バクテリオファージ
Zhang et al. Fisetin lowers Streptococcus suis serotype 2 pathogenicity in mice by inhibiting the hemolytic activity of suilysin
KR100988771B1 (ko) 엔테로코쿠스 및 스트렙토코쿠스 특이적 사멸능을 갖는 신규한 리신 단백질
KR20180042748A (ko) 신규한 포도상구균 특이 박테리오파지 sa7 및 이를 포함하는 항균 조성물
WO2021079536A1 (fr) Composition bactériophage
KR100914163B1 (ko) 황색포도상구균에 특이적인 포도비리대 박테리오파지유래의 항균 단백질
WO2021079986A1 (fr) Composition bactériophage
WO2021157732A1 (fr) Agent destiné à être utilisé comme bactériophage
KR101871342B1 (ko) 신규한 살모넬라균 특이 박테리오파지 st1 및 이를 포함하는 항균 조성물
KR20180073489A (ko) 신규한 녹농균 특이 박테리오파지 pa4 및 이를 포함하는 항균 조성물
EP3215174B1 (fr) Monocines et procédés d&#39;utilisation
Ali et al. Extraction, purification and therapeutic use of bacteriophage endolysin against multi-drug resistant Staphylococcus aureus: In vivo and in vitro study.
KR102037383B1 (ko) 신규한 비브리오균 특이 박테리오파지 vp2 및 이를 포함하는 항균 조성물
KR102037398B1 (ko) 신규한 살모넬라균 특이 박테리오파지 sg102 및 이를 포함하는 항균 조성물
KR101842673B1 (ko) 신규한 살모넬라균 특이 박테리오파지 se1 및 이를 포함하는 항균 조성물
US20060062775A1 (en) Method for the production of protamine
KR101595976B1 (ko) 황색포도알균에 특이적 항균 활성을 가지는 리신 융합 단백질 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20878908

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20878908

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP